Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

The Lancet Oncology

Volumn 18, Issue 2, 2017, Pages 212-220

  Plimack, Elizabeth R ^a   Bellmunt, Joaquim ^b   Gupta, Shilpa ^c   Berger, Raanan ^d   Chow, Laura Q M ^e   Juco, Jonathan ^f   Lunceford, Jared ^f   Saraf, Sanatan ^f   Perini, Rodolfo F ^f   O'Donnell, Peter H ^g  

^a FOX CHASE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d SHEBA MEDICAL CENTER   (Israel)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; BRAIN DISEASE; CANCER GROWTH; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CYTOLOGY; DEHYDRATION; DERMATITIS; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEART ARREST; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; ISRAEL; KIDNEY CANCER; MACULOPAPULAR RASH; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYOSITIS; NEUROMUSCULAR DISEASE; OPEN STUDY; PATIENT SAFETY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRURITUS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RHABDOMYOLYSIS; SEPSIS; STASIS DERMATITIS; STROMA CELL; SUBARACHNOID HEMORRHAGE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME; UNITED STATES; URETER CANCER; URETHRA CANCER; URINARY TRACT CANCER; UVEITIS; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SAFETY; SURVIVAL RATE; TUMOR RECURRENCE; URINARY TRACT TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SAFETY; SURVIVAL RATE; UROLOGIC NEOPLASMS;

EID: 85009252187     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30007-4     Document Type: Article

References (31)

1. 1 Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
2. 2 Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
3. 3 Genentech, Inc. Tecentriq (atezolizumab) injection, for intravenous use. 2016, 2016, Genentech, Inc, San Fransisco, CA.
4. 4 Powles, T, Eder, JP, Fine, GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
5. 5 Pardoll, DM, The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
6. 6 Hirano, F, Kaneko, K, Tamura, H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (2005), 1089–1096.
7. 7 Keir, ME, Butte, MJ, Freeman, GJ, Sharpe, AH, PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
8. 8 Boorjian, SA, Sheinin, Y, Crispen, PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14 (2008), 4800–4808.
9. 9 Nakanishi, J, Wada, Y, Matsumoto, K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56 (2007), 1173–1182.
10. 10 Inman, BA, Sebo, TJ, Frigola, X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109 (2007), 1499–1505.
11. 11 Merck and Co, Inc. Keytruda prescribing information. October, 2016 update, 2016, Merck and Co, Inc, Whitehouse Station, NJ.
12. 12 Ribas, A, Wolchuck, JD, Robert, C, et al. Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab in 411 paitients with melanoma. Eur J Cancer, 51, 2015, e24.
13. 13 Robert, C, Ribas, A, Wolchok, JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
14. 14 Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
15. 15 Muro, K, Chung, HC, Shankaran, V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet 17 (2016), 717–726.
16. 16 Seiwert, TY, Burtness, B, Mehra, R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17 (2016), 956–965.
17. 17 Nanda, R, Chow, LQ, Dees, EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34 (2016), 2460–2467.
18. 18 Tumeh, PC, Harview, CL, Yearly, JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
19. 19 Dako Press Release. Dako, an agilent technologies company, announces FDA approval of new companion diagnostic for lung cancer. http://www.dako.com/dk/index/aboutdako/newsevents/news/pd-l1-ihc-22c3-press-release.htm#.V9XVaPl95pg, 2015 (accessed Sept 12, 2016).
20. 20 Bellmunt, J, Théodore, C, Demkov, T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27 (2009), 4454–4461.
21. 21 Sweeney, CJ, Roth, BJ, Kabbinavar, FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24 (2006), 3451–3457.
22. 22 Hamid, O, Robert, C, Daud, A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
23. 23 Sonpavde, G, Sternberg, CN, Rosenberg, JE, et al. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 11 (2010), 861–870.
24. 24 Massard, C, Gordon, MS, Sharma, S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
25. 25 Snyder, A, Makarov, V, Merghoub, T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
26. 26 Rizvi, NA, Hellmann, MD, Snyder, A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
27. 27 Van Allen, EM, Miao, D, Schilling, B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
28. 28 Hugo, W, Zaretsky, JM, Sun, L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165 (2016), 35–44.
29. 29 Wilcox, RA, Feldman, AL, Wada, DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114 (2009), 2149–2158.
30. 30 Herbst, RS, Soria, JC, Kowanetz, M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
31. 31 Chang, CH, Pearce, EL, Emerging concepts of T cell metabolism as a target of immunotherapy. Nat Immunol 17 (2016), 364–368.